- Home
- OFS vs MNOV Comparison
OFS vs MNOV Comparison
Compare OFS & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OFS | MNOV |
|---|---|---|
| Founded | 2001 | 2000 |
| Country | United States | United States |
| Employees | 53 | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.2M | 72.7M |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | OFS | MNOV |
|---|---|---|
| Price | $3.77 | $1.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 78.8K | 59.0K |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | ★ 17.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,360,807.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.44 | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $3.84 | $1.13 |
| 52 Week High | $9.80 | $1.96 |
Technical Indicators
Market Signals| Indicator | OFS | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 32.81 | 45.85 |
| Support Level | N/A | $1.40 |
| Resistance Level | $4.44 | $1.62 |
| Average True Range (ATR) | 0.16 | 0.10 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 0.75 | 45.43 |
Price Performance
Historical ComparisonAbout OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.